Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Factor X deficiency is an important complication of amyloidosis. It is associated with severe bleeding that is difficult to control with plasma or prothrombin complex concentrates. Splenectomy ameliorates the factor X deficiency, but achieving satisfactory haemostasis for this operation is problematic. We report that a new clotting concentrate, recombinant factor VIIa, readily controls bleeding and makes splenectomy feasible.
Boggio
L
L
Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Chicago, IL, USA.
Green
D
D
D000686:Amyloidosis / Q000150:complications* / Q000601:surgery; D000925:Anticoagulants / Q000627:therapeutic use*; D015944:Factor VIIIa / Q000627:therapeutic use*; D005171:Factor X Deficiency / Q000150:complications* / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006488:Hemostasis, Surgical; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D013156:Splenectomy
D000925:Anticoagulants; D011994:Recombinant Proteins; D015944:Factor VIIIa